AMERISAFE (AMSF)
(Delayed Data from NSDQ)
$50.17 USD
+0.48 (0.97%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $50.10 -0.07 (-0.14%) 6:22 PM ET
1-Strong Buy of 5 1
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
AMSF 50.17 +0.48(0.97%)
Will AMSF be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for AMSF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMSF
Here's Why You Should Hold Synchrony (SYF) in Your Portfolio
Here's Why Prudent Investors are Holding Aflac (AFL) Shares Now
AMSF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Income Stocks to Buy for March 25th
Why Is AMERISAFE (AMSF) Down 0.2% Since Last Earnings Report?
Are Finance Stocks Lagging AMERISAFE (AMSF) This Year?
Other News for AMSF
SCHD's Reconstitution Adds Too Many Stocks With Mediocre Quant Ratings
Dividend Champion, Contender, And Challenger Highlights: Week Of March 17
AMERISAFE Announces Date of Annual Meeting of Shareholders and Record Date
Dividend Champion, Contender, And Challenger Highlights: Week Of March 3
AMSF Crosses Above Average Analyst Target